The GLP-1 Era: Obesity, Kidney, Heart, and Brain

For some time now, an interesting scene has been repeating itself in the clinic. A significant number of patients over 60, slightly overweight, with borderline blood pressure and diabetes, now sit down with the same question: "Doctor, would those GLP-1 injections work for me too?" The molecules we used to call "diabetes medication" now play a role in a much wider range of conditions, from cardiovascular disease and dementia to kidney and liver problems. Marketing a treatment that affects so many different organs as a "weight-loss injection" might actually be focusing on the most tedious part of the story.

Incretins, which are hormones secreted from the gut, are messengers that send a message to the pancreas: "Food is coming, prepare insulin." GLP-1 receptor agonists, a new generation of drugs that amplify this signal and also involve GLP and glucagon receptors, are essentially turbo versions of this messenger system. At the cellular level, they both reduce energy intake and alter the way energy is used. While reducing appetite, they increase lipolysis in fat tissue, fat oxidation in the liver, and in some combinations, energy expenditure. Simultaneously, they make pancreatic beta cells work more efficiently and curb the liver's tendency to raise blood sugar , thus calming both fasting and postprandial glycemia. The cardiovascular aspect is not just about "lose weight, lower blood pressure"; it involves a series of signaling changes in endothelial cells, macrophages, and smooth muscle cells in the vessel walls, reducing inflammation and plaque imbalance.

The clinical history of these drugs actually begins with diabetes, but it doesn't end there. In type 2 diabetes, they significantly reduce HbA1c and also promote weight loss. The next act is cardiovascular outcomes: some GLP-1 agonists and GIP–GLP-1 dual agents like tirzepatide manage to reduce major cardiovascular events by around 10–25 percent . Moreover, this is seen not only in diabetics but also in obese individuals without a diabetes diagnosis who have known vascular disease. This suggests a glycemic-independent vascular biology effect.

The picture is even more interesting on the kidney side. Classically, we used to say "if blood sugar improves, the kidneys are protected," but the data shows that these drugs reduce albuminuria and slow the rate of GFR decline, even flattening the GFR curve over the years in patients with advanced chronic kidney disease. This kidney-protective effect has a much larger component than can be explained solely by blood sugar or blood pressure reduction. It can directly suppress inflammation and fibrosis through the vascular and connective tissue cells in the kidney. In other words, a molecule advertised as a "weight-loss injection" also plays the role of an agent that nephrologists have dreamed of for years: slowing down the accelerated aging of the kidney .

When it comes to obesity itself, the situation is a bit more complex. In terms of weight loss, there are significant differences in potency between liraglutide, semaglutide, and tirzepatide. High doses of semaglutide can result in weight loss of up to 15%, while higher doses of tirzepatide can lead to weight loss exceeding 20%. Interestingly, weight regain occurs almost at the same rate when the medication is discontinued – it's as if biology is telling us, "I've coded this as a chronic condition; don't think of it as a short-term weight loss camp." Furthermore, weight loss varies greatly between individuals; one patient taking the same dose might lose 20%, while another might maintain the same level, or even gain a small amount of weight. This variability indicates the influence of many factors, from genetics and sleep patterns to muscle mass and concomitant medications.

There are also positive results in diseases clustered around obesity. It seems possible to reduce the rate of progression from prediabetes to diabetes by more than two-thirds with these drugs. In some cases, even after treatment is discontinued, glucose metabolism is observed to maintain its "good habits" for a while longer. Heart failure, especially the form with preserved ejection fraction, i.e., "normal pumping power but impaired filling," is very closely linked to obesity. Here, semaglutide and tirzepatide both promote weight loss and improve exercise capacity and symptom scores, delaying the first heart failure attack. This is a serious paradigm shift in an area where we said for years that "there are no drugs specifically for this group." On the liver side, in the MASLD/MASH spectrum, which is fatty liver disease, there is data showing both a reduction in steatosis and a beginning of the fibrosis phase. Semaglutide has therefore received approval for this indication, and preparations are underway for an application for tirzepatide. We see a similar situation in sleep apnea and gonarthrosis. Studies have shown that weight loss lowers the apnea-hypopnea index below the therapeutic threshold, and significantly improves knee pain and function scores.

Despite this otherwise bright picture, biology, as always, adds its own little footnotes. Rare but troubling events have been reported with potent GLP-1 agonists and tirzepatide around the optic nerve and retina. A range of side effects exist, from non-arteritic ischemic optic neuropathy to retinal tears. While some databases support this risk, other studies find no significant association. For now, it seems like a very low but not negligible possibility. The mechanism is also debated as a stress response of nerve tissue adapted to long-term hyperglycemia to rapid glucose drops. Another grey area is muscle and muscle-fat balance. With these drugs, lean mass is lost along with fat during weight loss. The fact that approximately half of this is skeletal muscle poses a theoretical risk, especially for older and already sarcopenic individuals. On the other hand, there is also the possibility of increased muscle quality due to reduced intramuscular fat. That is, a smaller but more “efficient” muscle tissue may be involved. While there is no systematic data yet showing dramatic functional outcomes such as "being unable to get up from the chair anymore," it is clear that when trying to help an elderly patient lose 15-20% of their weight rapidly, their strength reserves must also be taken into account.

Looking to the future, the scientific world isn't being very modest. With GLP-1 agonists supplemented with GIP, glucagon, and amylin in dual and triple forms; oral small molecule GLP-1 agonists; and hybrids that bind antagonistic antibodies to the GIP receptor and combine them with GLP-1, it seems we're relying a little too much on the fine-tuning of metabolism. Triple agonists like retatrutide report weight loss exceeding 20 kg, and agents like maridebart-cafraglutide, administered monthly, report double-digit, long-lasting effects, but the price is generally paid in the form of high rates of nausea and vomiting, and a significant number of treatment discontinuations. The era of "the more receptors, the better" will likely be tempered by the objection, "yes, but the stomach has its limits."

Amidst all this biological storm, common mistakes in the field of application remain largely unchanged. Incretin-based drugs are sometimes prescribed as cosmetic tools for rapid weight loss, completely disregarding sleep, nutritional quality, and resistance training. However, while some of the kidney and heart-protective effects come from the drug itself, the main factor in preserving muscle mass is still mechanical load—that is, the actual use of the muscle. In an elderly patient, it is not difficult to see a shift towards a sarcopenic phenotype due to rapid weight loss with these drugs, simultaneous protein deficiency, and immobility. On the other hand, it is equally problematic to tell elderly patients with multiple chronic diseases and frailty, low body mass index but significant abdominal fat—what we might call sarcopenic obesity—that "your weight is normal, this drug is not for you," thus depriving them of the heart-kidney protective effects. In short, when decisions are made solely based on the numbers on the scale, the real message of biology is missed.

Another blind spot is age and the brain. There is animal data suggesting GLP-1 may be neuroprotective, small studies showing it alleviates motor decline in Parkinson's disease, and some analyses indicating it may reduce the risk of dementia. However, a large, well-designed study in Alzheimer's showed that it did not significantly slow the progression of the disease. So yes, these drugs likely give the brain a breather by reducing vascular damage, but it's both too early and too optimistic to call them a "miracle cure for dementia." In the field of addiction, the results with nicotine, alcohol, and opioids are varying, sometimes promising, sometimes neutral. This reminds us that tampering with the brain's reward circuits is not as linear a task as tampering with pancreatic beta cells.

Ultimately, we have powerful tools that reframe metabolism on many levels. But like any powerful tool, how it's used, in what context, and at what speed will make the real difference. The same molecule might be an "early intervention opportunity" for a 45-year-old who is severely obese, has sleep apnea, MASLD, and has not yet shown significant muscle loss; while for an 82-year-old, frail, mildly diabetic patient with a history of falls and low muscle mass, it requires a more careful, slower intervention, perhaps at a lower dose, and necessarily integrated with resistance training, protein intake, and balance exercises. A "same dose, same target, same speed for everyone" approach would be unfair to the biological complexity of these drugs.

Perhaps asking ourselves these questions will allow us to look at this situation more calmly: What are we really prioritizing in this patient; weight, heart attack risk, kidney curve, or functional independence? Does our weight loss goal consider muscle-to-fat balance, or are we just chasing body mass index? Will this person's age, hormonal status, concomitant medications, sleep quality, and stress level make this treatment a lever or a boomerang? And most importantly, with such powerful pharmacological tools at our disposal, do we still have the patience to keep movement, sleep, nutrition, and muscle strength as the backbone of treatment? The answers will vary from person to person, but the real task is to ask the questions better.